Clinical trial
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
NCT04712669 is registered in ClinicalTrials.gov with Altavant Sciences GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
- Lead sponsor
- Altavant Sciences GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 15, 2021
- Completion date
- August 28, 2023
- Enrollment
- 108 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.